首发精神分裂症；阿立哌唑；氯氮平；潘氏量表；副反应量表

阿立哌唑与氯氮平治疗首发精神分裂症对照研究

http://www.100md.com 《临床心身疾病杂志》 2007年第2期

首发精神分裂症；阿立哌唑；氯氮平；潘氏量表；副反应量表,,首发精神分裂症；阿立哌唑；氯氮平；潘氏量表；副反应量表,1对象与方法,2结果,3讨论,参考文献

     【摘要】目的探讨阿立哌唑治疗首发精神分裂症的疗效及安全性。方法将74例首发精神分裂症患者随机分为研究组(阿立哌唑组)36例、对照组(氯氮平组)38例。疗程8 w。采用潘氏量表、副反应量表评定临床疗效和不良反应。结果治疗8 w末研究组总有效率83.33%，对照组81.58%，两组疗效相当。潘氏量表评分两组间同期比较无显著性差异(P>0.05)；组内治疗前后比较均有极显著性差异(P<0.01)。研究组认知功能、阴性症状改善优于对照组(P<0.05)，且不良反应发生率亦显著低于对照组。结论阿立哌唑治疗首发精神分裂症疗效与氯氮平相当，但对于认知功能、阴性症状的改善优于氯氮平，且安全性、依从性较好。

    【关键词】首发精神分裂症；阿立哌唑；氯氮平；潘氏量表；副反应量表

    A control study of aripirazole and clozapine in the treatment of firstepisode schizophrenia

    Yu Lin，Li Bin

    (The Affiliated Hospital of Henan Coal Health School, Pingdingshan 467013,Henan,China)

    【Abstract】 Objective To explore the curative effects and safety of aripiprazole in the treatment of firstepisode schizophrenia. Methods 74 patients with firstepisode schizophrenia were randomly divided into research(n=36, took aripiprazole ) and control(n=38,did clozapine) for 8 weeks. Curative effects were assessed with the Positive and Negative Syndrome Scale(PANSS) and adverse reactions with the Treatment Emergent Symptom Scale(TESS), respectively. Results At the end of the 8th week, total rates were 83.33% in the research and 81.58% in the control group, which showed therapeutic equivalence. In corresponding period score of the PANSS had no difference between the 2 groups(P>0.05); intragroup comparisons showed very significant difference between pre and posttreatment(P<0.01). Improvements of cognitive function and negative symptoms were more significant(P<0.05) and incidence of adverse effects lower in the research than in the control group. Conclusion Aripirazole has therapeutic equivalence to clozapine in firstepisode schizophrenia, significantly improves cognitive function and negative symptoms and has higher safety and better compliance. ......

百拇医药网 http://www.100md.com/html/DirDu/2007/04/28/43/00/52.htm

您现在查看是摘要页，全文长 6819 字符。